Kheiridoost-Langaroodi Hanie, Shakouri Seyed Kazem, Amirpour Mahdi, Iranshahi Amir Mehdi, Farshbaf-Khalili Azizeh
Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition Research Center, Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
J Family Reprod Health. 2022 Mar;16(1):16-32. doi: 10.18502/jfrh.v16i1.8590.
To evaluate systematically the therapeutic effects of five herbal medicines ( and ) on bone turnover markers as a primary outcome. A comprehensive systematic search of the literature was conducted in the electronic databases consisting of the Cochrane Library, MEDLINE, Web of Science, Scopus, Embase, ProQuest, and Google scholar, as well as SID, Magiran, and Irandoc for Persian literature up to December 2020. All Randomized controlled trials and quasi-experiments evaluated the impact of studied herbal medicines on bone turnovers of Bone Specific Alkaline Phosphatase (BSAP), osteocalcin, C-terminal Telopeptide type 1 Collagen (CTX-I), Deoxypyridinoline (DPD) were analyzed. Sixteen interventional studies comprised 968 participants included in systematic review. Ten of eligible studies with 603 participants included in meta-analysis. C and did not have a significant effect on BSAP (SMD=-1.76, 95%CI: -6.85 to 3.33, p=0.50, I=0.99, 6 trials, 241 participants), CTx (SMD=-0.17ng/mL, 95%CI:-0.43 to 0.09, p=0.21, I=1.000, 5 trials, 216 participants), DPD (MD=0.82nmol/mmol, 95%CI:-0.05 to 1.68, p=0.06, I=0.000, 2 trials, 67 participants), osteocalcin (SMD=-2.02ng/mL, 95%CI:-4.49 to 0.45, p=0.11, I2=0.79, Six trials, 229 participants). As secondary outcomes, femoral neck Bone Mineral Density (BMD) increased significantly (p=0.03, I=0.12) but lumbar spine BMD didn't differ (p=0.28, I2=0.97). significantly increased total hip BMD (p<0.001, I=0.12). QiangGuYin containing as a combined Chinese medicine had significant effect on P1NP, β-CTx, and BMD. Studied herbs except for QiangGuYin had no significant effects on bone turnover markers. Due to high heterogeneity between trials, further high-quality trials are suggested.
以骨转换标志物的治疗效果作为主要指标，系统评价5种草药的疗效。在Cochrane图书馆、MEDLINE、科学网、Scopus、Embase、ProQuest和谷歌学术等电子数据库以及SID、Magiran和Irandoc中进行了全面的系统文献检索，检索截至2020年12月的波斯文献。分析了所有评估所研究草药对骨特异性碱性磷酸酶（BSAP）、骨钙素、I型胶原C端肽（CTX-I）、脱氧吡啶啉（DPD）骨转换影响的随机对照试验和准实验。16项干预性研究共968名参与者纳入系统评价。10项符合条件的研究共603名参与者纳入荟萃分析。[草药名称C]和[草药名称D]对BSAP（标准化均数差=-1.76，95%可信区间：-6.85至3.33，p=0.50，I²=0.99，6项试验，241名参与者）、CTX（标准化均数差=-0.17ng/mL，95%可信区间：-0.43至0.09，p=0.21，I²=1.000，5项试验，216名参与者）、DPD（平均差=0.82nmol/mmol，95%可信区间：-0.05至1.68，p=0.06，I²=0.000，2项试验，67名参与者）、骨钙素（标准化均数差=-2.02ng/mL，95%可信区间：-4.49至0.45，p=0.11，I²=0.79，6项试验，229名参与者）均无显著影响。作为次要指标，股骨颈骨密度显著增加（p=0.03，I²=0.12），但腰椎骨密度无差异（p=0.28，I²=0.97）。[草药名称E]显著增加了全髋骨密度（p<0.001，I²=0.12）。含有[草药名称F]的强骨饮作为一种复方中药对P1NP、β-CTX和骨密度有显著影响。除强骨饮外，所研究的草药对骨转换标志物均无显著影响。由于试验间异质性高，建议进一步开展高质量试验。
